RxDoctor Payments Data

Emily Weig, MD

Dermatology · Dubuque, IANPI 1992365894

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.3% of the total across 41 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by AbbVie at 28.4% of the total. Reporting peaked in 2024 at $750 and has fallen 88.6% since, to $86 in 2025.

$1,040in general payments, 2019–2025

Across 41 payments — averaging $25.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$295
  • UCB, Inc.$255
  • Lilly USA, LLC$146
  • Sanofi$105
  • Pfizer$88
  • Sun Pharmaceutical Industries Inc.$65
  • plus $86 from 3 others

What the payments were for

  • Food & beverage$97193%
  • Education$707%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,040 in reported general payments places this provider in the 55th percentile of 92 dermatology providers in Iowa.

See all dermatology providers in Iowa

Medicare billing

Part B allowed, 2024
$170,483
Medicare patients
588
Services billed
3,316

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Unoready PenSecukinumab21$241,769
Skyrizi PenRisankizumab-Rzaa11$239,218
Dupixent PenDupilumab55$208,261
Cosentyx Sensoready (2 Pens)Secukinumab15$104,901
Fluorouracil87$6,668
Acitretin16$6,420
Clobetasol Propionate89$3,840
Metronidazole33$3,272
Ketoconazole202$3,252
Ivermectin11$2,946
Fluocinonide55$2,666
Clindamycin Phosphate50$1,806
Doxycycline Monohydrate61$1,550
Triamcinolone Acetonide124$1,092
Mupirocin83$693

Paid to pharmacies, not to this prescriber.

Other dermatology in Dubuque

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →